AOD-9604 Dosage: How Pepti Prescribes It, in Units, mL and mg

Every price is all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. These are the typical printed directions; your own directions are the ones on your vial.

Pepti's directions are written in two forms, millilitres and units, because prescriptions are written in millilitres and insulin syringes are marked in units. On a U-100 insulin syringe, 1 unit is 0.01 mL, so 100 units is 1 mL and 25 units is 0.25 mL. A unit is a volume mark on the barrel, not a measure of how strong the medication is. People often search for "AOD-9604 units" or "how many mcg of AOD-9604", and the answer to both depends on the concentration printed on the label.

The milligram figure comes from that concentration. Pepti's AOD-9604 is supplied at 2 mg/mL, so:

That arithmetic is a way to read a label, not a way to set a dose. A vial labelled 10 mg is not a 10 mg dose: it is twenty 0.5 mg doses. If your label and your syringe seem to disagree, do not dose; message your care team. How long does a peptide vial last explains every number on a vial label in more detail.

Online AOD-9604 charts quote doses in micrograms, milligrams and units interchangeably, and the numbers only line up if you know the concentration. The chart below is the conversion for a 2 mg/mL vial, drawn with a U-100 insulin syringe. It is math only. It is not a menu of doses, and the only line that applies to you is the one that matches the number printed on your vial.

The rule behind every row: units divided by 100 gives millilitres, and millilitres multiplied by 2 gives milligrams. The same conversion applies to the AOD-9604 in the SHRED and PHYSIQ blends, because both carry AOD-9604 at 2 mg/mL. In a blend, every draw delivers all four peptides together in fixed proportion; there is no way to take more of one and less of another from the same vial.

A chart from another source, written for a different concentration, gives different milligram figures for the same units. Research-use vials sold online are often a powder you are expected to mix yourself, so the concentration depends on how much water was added. That is the main reason not to dose from a chart, including this one. Pepti vials are multi-dose solutions shipped ready to use, so the concentration on the label is the concentration in the vial.

At Pepti's typical directions, one 10 mg vial lasts four weeks:

Four weeks is why refills run every 28 days, one vial per fill. Vials ship refrigerated with ice packs, with sterile syringes and alcohol prep pads. Nothing is mixed at home. Keep the vial in the fridge between doses, and follow the beyond-use date printed on the label, which runs from first puncture. How to store peptides covers storage.

If a vial runs short before the refill, message your care team rather than adjusting anything yourself. If you miss a dose, follow your directions and do not take two doses to make up for one.

AOD-9604 is unusual among compounded peptides because it has been through randomised, placebo-controlled human trials: six of them, run in Australia between roughly 2001 and 2007 by the company that developed it, Metabolic Pharmaceuticals, enrolling close to 900 people. The doses in those trials are often quoted online as if they were injection protocols. They were not:

Two things matter about that table. First, every trial used oral or intravenous AOD-9604. There is no published human trial of the subcutaneous injection that is actually prescribed, which the FDA specifically noted in its 2024 review. An oral milligram and an injected milligram are not interchangeable, so the 0.5 mg in the OPTIONS trial and the 0.5 mg in a Pepti dose share a number, not an evidence base. Second, OPTIONS, the largest and best-designed trial, did not find statistically significant weight loss versus placebo, and on 21 February 2007 the company ended development for obesity.

The honest reading is that there is no human dose-ranging study for injected AOD-9604. The schedule in common use comes from prescribing convention and the vial arithmetic, not from a trial. That is why your directions come from a physician who has reviewed your intake, not from a study table. The full trial history is in what is AOD-9604, and the evidence benefit by benefit is in AOD-9604 benefits.

Both blends contain 10 mg of AOD-9604 in a 5 mL vial, the same 2 mg/mL concentration as the standalone vial, so the AOD-9604 per dose is identical. What changes is everything else in the draw.

AOD-9604 on its own leaves the growth hormone axis alone: cell work reports it does not bind the growth hormone receptor, and the human trials reported no change in IGF-1. Both blends deliberately pair it with peptides that do act on that axis. No study has tested either blend as a blend. A single-agent vial is the simpler option if your physician wants to see what one compound does before adding others. The blends are compared in PHYSIQ vs SHRED vs TITAN, and each is covered in what is SHRED and what is PHYSIQ.

Your physician sets your directions after reviewing your intake. Things that can lead to different directions, or a different product, include:

When directions change, the new numbers are printed on the new label. Never carry a number over from a previous fill. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

AOD-9604 has more human safety data than most compounded peptides, because of the six company trials. The full picture is in AOD-9604 side effects.

In the trials, adverse events were similarly distributed between AOD-9604 and placebo, IGF-1 did not change, glucose tolerance was not impaired, and no anti-AOD-9604 antibodies were detected in the subjects tested. The longest trial ran 24 weeks, and no trial used the subcutaneous route.

AOD-9604 has no FDA-approved product. On 4 December 2024 the FDA's Pharmacy Compounding Advisory Committee voted 0 to 12 against adding it to the 503A Bulks List for obesity; that is a recommendation, and the FDA has not issued a final rule. It is legal for a physician to prescribe and a licensed pharmacy to compound, and compounded medications are not FDA approved. Tested athletes should know the WADA List names AOD-9604 under S2.2.3 as a growth hormone fragment, prohibited at all times.

AOD-9604 cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for what is in the vial: identity, purity, sterility and concentration are untested, so even the concentration your units chart depends on is unknown. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and dose changes.

Pepti prescribes AOD-9604 in every state except Oklahoma, plus DC Step by step: how to get AOD-9604 prescribed online and how to get the SHRED Blend prescribed online. How it compares with tesamorelin is in AOD-9604 vs tesamorelin.